Document Detail


Mitochondria: Prospective Targets for Neuroprotection in Parkinson's Disease.
MedLine Citation:
PMID:  24606805     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Parkinson's disease is the second most common neurodegenerative disorder characterized by persistent loss of dopaminergic neurons in the SN and clinically associated with cognitive, behavioral and motor deficits. There is an enormous amount of data that provides convincing evidence about the prime involvement of mitochondria in the onset and progression of neurodegeneration. Several studies have also emphasized that accumulation of toxic protein and their aggregates in mitochondria lead to energy deficits, excessive ROS generation, mutations in mitochondrial genome and proteins regulating mitochondrial homeostasis, and impaired mitochondrial dynamics in animal models of PD and patients. Here we discuss about the bioenergetic agents, which have been tested for reducing the mitochondrial dysfunction and associated disease pathology in cellular and animal models of PD and PD patients with encouraging outcomes. We also provide a succinct overview of current therapeutic implications of PGC-1α, SIRT, AMPK, and Nrf2-ARE as salutary targets to overcome the deleterious effects posed by mitochondrial dysfunction in the onset and progression of PD.
Authors:
Anuradha Yadav; Swati Agrawal; Shashi Kant Tiwari; Rajnish K Chaturvedi
Related Documents :
25246695 - Predictors of severe disease in melioidosis patients in kuala lumpur, malaysia.
12135635 - Experimental transmission of epizootic bovine abortion (foothill abortion).
11054725 - Differential expression of laminin chains and anti-laminin autoantibodies in experiment...
25466755 - Assessing and treating fever in returned travellers.
22062195 - Natural history of end-stage lv dysfunction: has it improved from the classic franciosa...
6844195 - Pathological aspects of endomyocardial fibrosis.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-3-05
Journal Detail:
Title:  Current pharmaceutical design     Volume:  -     ISSN:  1873-4286     ISO Abbreviation:  Curr. Pharm. Des.     Publication Date:  2014 Mar 
Date Detail:
Created Date:  2014-3-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602487     Medline TA:  Curr Pharm Des     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mitochondrial Biogenesis: a Therapeutic Target for Neurodevelopmental Disorders and Neurodegenerativ...
Next Document:  Impact of diabetes on uric acid and its relationship with the extent of coronary artery disease and ...